Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Bardin

Showing results (31-40 of 195) with videos related to

Pageof 20
Sort By:
Expert Opinion on Pharmacotherapy|November 6, 2010
Colchicine for the treatment of goutPascal Richette, Thomas Bardin
Nature Reviews. Rheumatology|August 1, 2019
Defining remission in patients with goutThomas Bardin, Pascal Richette
Lancet (London, England)|November 12, 2020
FAST: new look at the febuxostat safety profileThomas Bardin, Pascal Richette
Current Opinion in Rheumatology|January 17, 2015
Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in goutPascal Richette, Aline Frazier, Thomas Bardin
Joint Bone Spine|September 3, 2003
Estrogens, cartilage, and osteoarthritisPascal Richette, Maïté Corvol, Thomas Bardin
Rheumatology (Oxford, England)|April 25, 2014
Prophylaxis for acute gout flares after initiation of urate-lowering therapyAugustin Latourte, Thomas Bardin, Pascal Richette
Rheumatology (Oxford, England)|April 29, 2009
An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition diseasePascal Richette, Thomas Bardin, Michael Doherty
Presse Medicale (Paris, France : 1983)|June 21, 2011
[New therapeutic options for gout]Pascal Richette, Sébastien Ottaviani, Thomas Bardin
Expert Opinion on Drug Metabolism & Toxicology|May 10, 2014
Pharmacokinetics considerations for gout treatmentsPascal Richette, Aline Frazier, Thomas Bardin
Joint Bone Spine|October 24, 2007
Achondroplasia: from genotype to phenotypePascal Richette, Thomas Bardin, Chantal Stheneur
Pageof 20

Showing results (31-40 of 195) with videos related to

Sort By:
Pageof 20
Expert Opinion on Pharmacotherapy|November 6, 2010
Colchicine for the treatment of goutPascal Richette, Thomas Bardin
Nature Reviews. Rheumatology|August 1, 2019
Defining remission in patients with goutThomas Bardin, Pascal Richette
Lancet (London, England)|November 12, 2020
FAST: new look at the febuxostat safety profileThomas Bardin, Pascal Richette
Current Opinion in Rheumatology|January 17, 2015
Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in goutPascal Richette, Aline Frazier, Thomas Bardin
Joint Bone Spine|September 3, 2003
Estrogens, cartilage, and osteoarthritisPascal Richette, Maïté Corvol, Thomas Bardin
Rheumatology (Oxford, England)|April 25, 2014
Prophylaxis for acute gout flares after initiation of urate-lowering therapyAugustin Latourte, Thomas Bardin, Pascal Richette
Rheumatology (Oxford, England)|April 29, 2009
An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition diseasePascal Richette, Thomas Bardin, Michael Doherty
Presse Medicale (Paris, France : 1983)|June 21, 2011
[New therapeutic options for gout]Pascal Richette, Sébastien Ottaviani, Thomas Bardin
Expert Opinion on Drug Metabolism & Toxicology|May 10, 2014
Pharmacokinetics considerations for gout treatmentsPascal Richette, Aline Frazier, Thomas Bardin
Joint Bone Spine|October 24, 2007
Achondroplasia: from genotype to phenotypePascal Richette, Thomas Bardin, Chantal Stheneur
Pageof 20